Ultragenyx Pharmaceutical Inc
Most Recent
Company & Industry OverviewsPTC Therapeutics to Acquire Agilis Biotherapeutics
On July 19, PTC Therapeutics (PTCT) agreed to acquire Agilis Biotherapeutics. The acquisition is expected to close during Q3 2018.
Company & Industry Overviews Discretionary Stocks Boost the Wells Fargo Growth Fund in YTD 2016
Early 2016 was not generous to the Wells Fargo Growth Fund – Class A (SGRAX), and the fund was a below-average performer until May. However, things have improved since then.
Company & Industry OverviewsCan XBI Continue the Upward Trend It Achieved in May?
The SPDR S&P Biotech ETF (XBI) reflected the performance of SPY and rose 0.2%, continuing its upward trend. XBI had a good month in May and began June on a positive note.
Company & Industry Overviews How the Consumer Discretionary Sector Has Affected SGRAX in 2016
The Wells Fargo Growth Fund Class A (SGRAX) had fallen by 1% year-to-date (or YTD) in 2016 as of May 27, 2016.
Company & Industry OverviewsIBB’s Mid-Cap Stocks: Kite Pharma Drug Gets Orphan Drug Status
IBB’s mid-cap holding Kite Pharma (KITE) rose by 3.3% on the news of the FDA granting orphan drug status to Kite’s KTE-C19.
Company & Industry OverviewsMid-Cap Stock Update: Horizon Tanks 21% on Earnings Concerns
In the mid-cap space, Horizon Pharma (HZNP) was the worst hit, falling by 21% for the week ended April 15, 2016.
Company & Industry OverviewsXBI News as of March 16: Mid-Caps Under Pressure
Given selling pressures, XBI’s 18 mid-cap stocks went down marginally on average, losing 0.4% on March 16. Eight stocks advanced while ten stocks declined.
Company & Industry OverviewsUltragenyx Woos Investors with Good Returns in Mid-Cap Space
Ultragenyx Pharmaceutical (RARE) rebounded on December 14, 2015, after falling for four consecutive days. The stock rose 3.8% and was the top performer among the mid-cap stocks that day.
Company & Industry OverviewsMoving Averages of XBI’s Holdings Have Improved
The moving averages of the stocks in the SPDR S&P Biotech ETF (XBI) have seen drastic improvements recently.
Company & Industry OverviewsShire-Dyax Merger Drove Biotech Stocks
Shire (SHPG) announced that it will acquire Dyax (DYAX) for $37.30 per Dyax share in a deal valued at ~$5.9 billion.
Company & Industry OverviewsUltragenyx: A Top Loser in the Biotechnology Subgroup
Ultragenyx Pharmaceutical (RARE) fell by 8.2% due to profit-booking. It had a high trading volume of ~700,000 shares. The stock closed at $86.99.